

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 June 2023 (15.06.2023)



(10) International Publication Number
WO 2023/108015 A1

(51) International Patent Classification:

A61K 31/216 (2006.01) *A61K 31/015* (2006.01)
A61K 31/4709 (2006.01) *A61K 31/01* (2006.01)
A61K 31/215 (2006.01) *A61P 35/00* (2006.01)

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/081104

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

07 December 2022 (07.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/286,981 07 December 2021 (07.12.2021) US

(71) Applicants: **IO THERAPEUTICS, INC.** [US/US]; 9450
Pinecroft Drive, Unit 9497, Spring, Texas 77387 (US).
BOARD OF REGENTS, THE UNIVERSITY OF TEX-
AS SYSTEM [US/US]; 210 West 7th Street, Austin, Texas
78701 (US).

(72) Inventors: **SANDERS, Martin E.**; 9450 Pinecroft Drive,
Unit 9497, Spring, Texas 77387 (US). **BROWN, Powell**
H.; University of Texas MD Anderson Cancer Center, 6767
Bertner Avenue, Suite 8344, Houston, Texas 77030 (US).
MOYER, Cassandra; University of Texas MD Anderson
Cancer Center, 6767 Bertner Avenue, Suite 8344, Houston,
Texas 77030 (US). **MAZUMDAR, Abhijit**; University of
Texas MD Anderson Cancer Center, 6767 Bertner Avenue,
Suite 8344, Houston, Texas 77030 (US).

(74) Agent: **GLASKY BERGMAN, Michelle**; 1 Park Plaza,
Twelfth Floor, Irvine, California 92614 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2⁺ CANCERS

(57) Abstract: The present specification provides combinations of active agents for the improved treatment of Her2⁺ cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.

WO 2023/108015 A1